Werewolf Therapeutics (NASDAQ:HOWL) Given “Outperform” Rating at Wedbush

Wedbush reiterated their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research report sent to investors on Monday morning, RTT News reports. They currently have a $9.00 price objective on the stock.

HOWL has been the subject of a number of other reports. HC Wainwright reaffirmed a buy rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Monday. JMP Securities reaffirmed a market outperform rating and set a $12.00 price objective on shares of Werewolf Therapeutics in a report on Monday.

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $5.98 on Monday. The stock has a 50 day simple moving average of $6.21 and a 200-day simple moving average of $4.67. Werewolf Therapeutics has a 12-month low of $1.57 and a 12-month high of $8.19. The company has a debt-to-equity ratio of 0.29, a current ratio of 7.14 and a quick ratio of 7.14.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.10. The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.75 million. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. Equities research analysts expect that Werewolf Therapeutics will post -1.38 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

Several large investors have recently modified their holdings of the business. PFM Health Sciences LP raised its position in shares of Werewolf Therapeutics by 35.6% during the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after purchasing an additional 909,895 shares during the last quarter. Denali Advisors LLC acquired a new position in shares of Werewolf Therapeutics in the first quarter worth $172,000. Lighthouse Investment Partners LLC purchased a new stake in shares of Werewolf Therapeutics in the fourth quarter valued at $87,000. Certuity LLC acquired a new stake in shares of Werewolf Therapeutics during the fourth quarter valued at $39,000. Finally, Financial Perspectives Inc increased its position in Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after purchasing an additional 3,000 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.